Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy

Página do item simplificado
dc.citation.volumev. 9
dc.contributor.authorOliveira-Giacomelli, Agatha
dc.contributor.authorNaaldijk, Yahaira
dc.contributor.authorSarda-Arroyo, Laura
dc.contributor.authorGoncalves, Maria C. B. [UNIFESP]
dc.contributor.authorCorrea-Velloso, Juliana
dc.contributor.authorPillat, Micheli M.
dc.contributor.authorSouza, Hellio D. N. de
dc.contributor.authorUlrich, Henning
dc.coverageLausanne
dc.date.accessioned2020-07-20T16:31:00Z
dc.date.available2020-07-20T16:31:00Z
dc.date.issued2018
dc.description.abstractSince proving adenosine triphosphate (ATP) functions as a neurotransmitter in neuron/glia interactions, the purinergic system has been more intensely studied within the scope of the central nervous system. In neurological disorders with associated motor symptoms, including Parkinson's disease (PD), motor neuron diseases (MND), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Huntington's Disease (HD), restless leg syndrome (RLS), and ataxias, alterations in purinergic receptor expression and activity have been noted, indicating a potential role for this system in disease etiology and progression. In neurodegenerative conditions, neural cell death provokes extensive ATP release and alters calcium signaling through purinergic receptor modulation. Consequently, neuroinflammatory responses, excitotoxicity and apoptosis are directly or indirectly induced. This review analyzes currently available data, which suggests involvement of the purinergic system in neuro-associated motor dysfunctions and underlying mechanisms. Possible targets for pharmacological interventions are also discussed.en
dc.description.affiliationUniv Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Sch Med, Dept Neurol & Neurosci, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Sch Med, Dept Neurol & Neurosci, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipSao Paulo State Foundation FAPESP
dc.description.sponsorshipNational Research Council CNPq, Brazil
dc.description.sponsorshipIDFAPESP: 2012/50880-4
dc.description.sponsorshipIDFAPESP: 2012/20685-5
dc.description.sponsorshipIDFAPESP: 2013/25338-4
dc.description.sponsorshipIDFAPESP: 2012/20685-5
dc.description.sponsorshipIDFAPESP: 2015/194783
dc.description.sponsorshipIDFAPESP: 2015/14343-2
dc.description.sponsorshipIDCNPq: 306429/2013-6
dc.description.sponsorshipIDCNPq: 141979/2014-3
dc.description.sponsorshipIDCNPq: 870458/1997-3
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.3389/fphar.2018.00325
dc.identifier.citationFrontiers In Pharmacology. Lausanne, v. 9, p. -, 2018.
dc.identifier.doi10.3389/fphar.2018.00325
dc.identifier.fileWOS000429572100001.pdf
dc.identifier.issn1663-9812
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/55640
dc.identifier.wosWOS:000429572100001
dc.language.isoeng
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers In Pharmacology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectParkinson's diseaseen
dc.subjectamyotrophic lateral sclerosis (ALS)en
dc.subjectmultiple sclerosisen
dc.subjectneurodegenerationen
dc.subjectataxiaen
dc.subjectHuntington's diseaseen
dc.subjectrestless leg syndromeen
dc.subjectpurinergic receptorsen
dc.titlePurinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapyen
dc.typeinfo:eu-repo/semantics/review
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000429572100001.pdf
Tamanho:
1.36 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos